Close Menu

hepatitis

The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays. 

Researchers reported on findings from analyses on whole-genome sequences and other features from three fowl adenoviruses found in China during 2012 or 2013.

The company is developing a prototype system that it aims to later validate in clinical samples.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

In Cell this week: GWAS with immunophenotyping to examine genetic architecture of the immune system, hepatitis C virus sequesters miR-122 during infection, and more.

The findings also provide new clues about the virus' well-established association with hepatocellular carcinoma.

The new company will be focused entirely on hepatitis B, although officials previously said that Tekmira's other non-HBV RNAi programs would continue to advance.

The new assay expands a portfolio of viral load monitoring tests for the Cobas 6800 and 8800 systems.

The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.

The company also recently paid $7 million for an exclusive option on an undisclosed RNAi technology and related intellectual property.

Pages

The Chan Zuckerberg Biohub is working with California's health department to sequence viral samples from COVID-19 patients to trace viral introductions, according to the San Francisco Chronicle.

Despite differences in their migration habits, eastern and western monarch butterflies are genetically similar, according to a study in Molecular Ecology.

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

In PLOS this week: identification of fungal species in subcutaneous infections, sequencing of Campylobacter found in raw meat from retail stores, and more.